WallStreetZenWallStreetZen

NASDAQ: AVLN
Avalyn Pharma Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for AVLN

Based on 3 analysts offering 12 month price targets for Avalyn Pharma Inc

Min Forecast
$51.00+98.6%
Avg Forecast
$61.33+138.84%
Max Forecast
$80.00+211.53%

Should I buy or sell AVLN stock?

Based on 3 analysts offering ratings for Avalyn Pharma Inc.

Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although AVLN's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates AVLN as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their AVLN stock forecasts and price targets.

AVLN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-05-26
lockedlocked$00.00+00.00%2026-05-26
lockedlocked$00.00+00.00%2026-05-26

1 of 1

Forecast return on equity

Is AVLN forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is AVLN forecast to generate an efficient return on assets?

Company
-74.33%
Industry
27.22%
AVLN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

AVLN earnings per share forecast

What is AVLN's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$2.78
Avg 2 year Forecast
-$2.23
Avg 3 year Forecast
-$2.12

AVLN revenue forecast

What is AVLN's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

AVLN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
AVLN$25.68$61.33+138.84%Strong Buy
MGTX$12.33$24.17+96.00%Strong Buy
SVRA$5.52N/AN/A
ORIC$10.73$19.33+80.18%Strong Buy
XNCR$14.95$22.67+51.62%Strong Buy
View Top Biotech Stocks

Avalyn Pharma Stock Forecast FAQ

Is Avalyn Pharma Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: AVLN) stock is to Strong Buy AVLN stock.

Out of 3 analysts, 2 (66.67%) are recommending AVLN as a Strong Buy, 1 (33.33%) are recommending AVLN as a Buy, 0 (0%) are recommending AVLN as a Hold, 0 (0%) are recommending AVLN as a Sell, and 0 (0%) are recommending AVLN as a Strong Sell.

If you're new to stock investing, here's how to buy Avalyn Pharma stock.

What is AVLN's earnings growth forecast for 2026-2028?

(NASDAQ: AVLN) Avalyn Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.15%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.17%.

Avalyn Pharma's earnings in 2026 is N/A.On average, 5 Wall Street analysts forecast AVLN's earnings for 2026 to be -$123,449,936, with the lowest AVLN earnings forecast at -$149,890,194, and the highest AVLN earnings forecast at -$98,219,972. On average, 5 Wall Street analysts forecast AVLN's earnings for 2027 to be -$98,729,803, with the lowest AVLN earnings forecast at -$114,698,583, and the highest AVLN earnings forecast at -$82,858,555.

In 2028, AVLN is forecast to generate -$93,830,996 in earnings, with the lowest earnings forecast at -$101,230,189 and the highest earnings forecast at -$84,720,545.

What is AVLN's revenue growth forecast for 2026-2028?

(NASDAQ: AVLN) Avalyn Pharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.03%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.96%.

Avalyn Pharma's revenue in 2026 is N/A.On average, 4 Wall Street analysts forecast AVLN's revenue for 2026 to be $0, with the lowest AVLN revenue forecast at $0, and the highest AVLN revenue forecast at $0. On average, 4 Wall Street analysts forecast AVLN's revenue for 2027 to be $0, with the lowest AVLN revenue forecast at $0, and the highest AVLN revenue forecast at $0.

In 2028, AVLN is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is AVLN's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: AVLN) forecast ROA is -74.33%, which is lower than the forecast US Biotechnology industry average of 27.22%.

What is AVLN's Price Target?

According to 3 Wall Street analysts that have issued a 1 year AVLN price target, the average AVLN price target is $61.33, with the highest AVLN stock price forecast at $80.00 and the lowest AVLN stock price forecast at $51.00.

On average, Wall Street analysts predict that Avalyn Pharma's share price could reach $61.33 by May 26, 2027. The average Avalyn Pharma stock price prediction forecasts a potential upside of 138.84% from the current AVLN share price of $25.68.

What is AVLN's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: AVLN) Avalyn Pharma's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that AVLN's EPS will be -$2.78 for 2026, with the lowest EPS forecast at -$3.38, and the highest EPS forecast at -$2.22. On average, analysts forecast that AVLN's EPS will be -$2.23 for 2027, with the lowest EPS forecast at -$2.59, and the highest EPS forecast at -$1.87. In 2028, AVLN's EPS is forecast to hit -$2.12 (min: -$2.28, max: -$1.91).

What is AVLN's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: AVLN) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.